Purpose: The aim of this study was to assess the dynamics of epicardiac adipose tissue (EAT) thickness and total volume as well as that of systolic and diastolic dysfunction in a group of patients with type 2 diabetes (T2D) after initiation of sodium glucose co-transporter 2 (SGLT 2) inhibitors therapy. Patients and methods: This prospective, observational study included 53 patients with T2D who received SGLT-2 inhibitors for 24 weeks. In all patients, echocardiographic screening for EAT, systolic and diastolic dysfunction and non-contrast computed tomography scans were performed, both before and after 24 weeks of SGLT-2 inhibition. Imagistic evaluation was followed by the association’s analysis between the dynamics of EAT and heart function, as well as the patient’s clinical and biological parameters. We considered a decrease or increase of more than 10% in EAT as being clinically significant. Results: The mean volume of EAT decreased significantly after SGLT 2 inhibition (37.8±17.2 vs. 20.7±7 cm³; p<0.001). Median values of EAT thickness also decreased significantly (5.95 vs. 3.01 mm; p<0.001). Most patients, 75.4% (40/53), presented more than 10% decrease in EAT volume, 9.5% (5/53) had stable EAT volume values, while in 15.1% (8/53) the means of EAT volume increased. 73.5% of the patients had diastolic dysfunction type 1 (DD 1) at baseline. No significant change was observed in the left ventricular ejection fraction or diastolic dysfunction after 24 weeks of treatment. Although not statistically significant, an improvement in cardiac function has been noticed throughout the duration of 1 year of treatment with SGLT 2 inhibitors. Conclusion: This study showed the beneficial effect of SGLT 2 inhibitors on EAT after a short period of treatment, but there were no significant changes in the systolic function during the 1st year of study. However, reducing epicardial fat has led to remission of diastolic dysfunction.

Introduction. Sodium is a crucial extracellular electrolyte for neuromuscular function, acid-base balance, cellular processes, and osmolarity regulation via transmembrane transport. Sodium deficiency, or hyponatremia, causes plasma hypoosmolarity, leading to water movement into tissues, cellular overhydration, and edema, especially within the brain. This study aimed to determine the cause of severe hyponatremia in a 65-year-old patient. Case Report. A 65-year-old patient was admitted to the emergency department of “Pius Brînzeu” County Emergency Clinical Hospital, Timișoara, Romania, presenting with severe general deterioration, asthenia, headache, vertigo, nausea, vomiting, and epigastric pain. Laboratory tests conducted at the emergency department confirmed the presence of severe hyponatremia. The patient was transferred to the Internal Medicine Clinic, where immediate treatment for hyponatremia was initiated. Subsequent biological and imaging investigations revealed adrenal insufficiency as the underlying cause of severe hyponatremia. Conclusions. Severe hyponatremia is a potentially life-threatening condition, with adrenal insufficiency as a significant underlying cause. Often overlooked due to subtle electrolyte disturbances, accurate diagnosis of secondary adrenal insufficiency is essential, as it requires lifelong hormonal replacement therapy. In such cases, targeted hydrocortisone therapy is vital for restoring hormonal balance, thus ensuring therapeutic efficacy and improving long-term patient outcomes.

Background/Objectives: Acinic cell carcinoma (ACC) is a rare lung neoplasm that can affect both children and adults as a parenchymal or endobronchial mass. It is histologically similar to this kind of tumor described in salivary glands, but with a different immunophenotype. In general, it poses a reduced degree of malignancy, with indolent growth and a favorable prognosis, with exceptionally rare cases associated with recurring disease or lymph node metastases. Methods: When clinicians are facing puzzling symptomatology in their patients, the main role of the multidisciplinary team in their review of oncological cases is to recommend imagistic-guided biopsies. Tissues samples were routinely processed, stained with hematoxylin-eosin (HE) and periodic acid–Schiff (PAS), and submitted to complementary immunohistochemistry tests. Results: Histopathological reports were consistent for lung ACC with regional lymph node involvement and remote metastases. Oncological therapies followed. Conclusions: Postponements of the presentation to the doctor at the onset of symptoms, as well as a lack of periodic health control for people insured by national health insurance companies, often lead to medical, human and financial complications that are difficult to manage. The pathologist involved in the discussion of oncological cases brings his expertise in solving cases, certifying the evolution of tumors considered less aggressive, such as in the case of lung ACCs.